English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduJennifer Raymond, MD, MCR, Chief of the Center for Endocrinology, Diabetes and Metabolism at Children’s Hospital Los Angeles, is co-leading an innovative multicenter study funded by a four-year R01 NIH grant testing a virtual peer group model—co-designed with youth and families—to increase diabetes technology use among Latinx adolescents.
Tag: Diabetes Technology
Closed-loop insulin delivery systems may improve blood sugar control in children with type 1 diabetes
Closed-loop insulin delivery systems improve glucose control in children with type 1 diabetes without causing adverse effects, according to a study presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
CGM alarms often not set to alert children with diabetes to harmful blood glucose fluctuations
Children and teenagers who use continuous glucose monitors (CGM) to manage diabetes often fail to use the appropriate alarm settings to alert to dangerously low or harmful high blood sugar levels, according to a study being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill. This variability makes the monitors less useful in tracking glucose levels.
ENDO 2023 press conferences to highlight emerging technology and diabetes research
Researchers will delve into the latest research in diabetes, obesity, reproductive health and other aspects of endocrinology during the Endocrine Society’s ENDO 2023 news conferences June 15-18.
Technology use by adults with type 1 diabetes lower among African Americans, Hispanics
Continuous glucose monitor (CGM) and continuous subcutaneous insulin infusion (CSII) devices are known to improve outcomes in patients with type 1 diabetes (T1D), yet African American and Hispanic patients face barriers to the use of these devices, according to results of a small single-center retrospective study. The results of the ENDO 2020 abstract will be published in the Journal of the Endocrine Society.
Medtronic MiniMed 670G insulin pump allows “excellent” blood glucose control
Patients with type 1 diabetes who use Medtronic’s MiniMedTM 670G insulin pump system are able to maintain blood glucose levels in the targeted range over 71% of the time, according to a study that analyzed some 6 million days of real-world data. Results of the industry-supported study were accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental issue of the Journal of the Endocrine Society.